Welcome!

News Feed Item

Epilepsy Foundation Presents Lifetime Accelerator Award to H. Steven White, Ph.D., for Contributions to the Field of Epilepsy and Seizures

Dr. White to Be Honored at 4th Biennial Epilepsy Pipeline Conference 2014 in San Francisco June 5-7

LANDOVER, MD--(Marketwired - May 29, 2014) - The Epilepsy Foundation announced today that H. Steven White, Ph.D., professor of pharmacology and toxicology and principal investigator of the National Institutes of Health (NIH)-sponsored Anticonvulsant Drug Development Program at the University of Utah College of Pharmacy, has been named the 2014 recipient of the Epilepsy Foundation's Lifetime Accelerator Award, in recognition of his commitment and pioneering contributions to the field of epilepsy and seizures. Dr. White will be honored at the 4th Biennial Epilepsy Pipeline Conference 2014, being held June 5-7, 2014, at the Hyatt Regency San Francisco.

A leader in translational research in anticonvulsant drug therapies, Dr. White is well-recognized for his scientific leadership of the University of Utah NIH-sponsored Anticonvulsant Drug Development (ADD) Program, founded in 1975 by the late Ewart A. Swinyard in collaboration with the National Institutes of Neurological Disorders and Stroke (NINDS), NIH. Dr. White's career in antiepileptic drug discovery began in 1986 as the senior scientist of the ADD Program. Over the three decades that mark Dr. White's research in the field, this program has played a crucial role in the early identification and characterization of thousands of novel anticonvulsant medications using established seizure and epilepsy models. Dr. White's laboratory has identified and characterized the anticonvulsant profile and potential mechanism of action for established and new anti-epilepsy agents. Notably, the efforts of the faculty, staff and students of this program, which Dr. White has directed since 2001, have since its establishment in 1975 contributed to the successful development of multiple new therapeutics, including felbamate, rufinamide, topiramate, retigabine and lacosamide.

"On behalf of the Epilepsy Foundation and many clinicians treating seizure conditions today, we are especially pleased to honor Dr. White with the Lifetime Accelerator Award and to recognize his outstanding contributions in anticonvulsant drug development," said Philip M. Gattone, president and CEO of the Epilepsy Foundation. "We are grateful not only for his steadfast commitment to our mission, but also for his energy and enthusiasm for mentoring the next generation of neuroscientists and epilepsy educators."

"Dr. White has been a force behind many of the therapeutics used in treatment today. He is truly dedicated to finding therapies that will make a difference to patients through development of new animal models," said Jacqueline A. French, M.D., director of the Epilepsy Study Consortium, and director of clinical trials at NYU's Comprehensive Epilepsy Center. "He has given generously of his free time to collaborate with other researchers and epilepsy organizations and this recognition is well-deserved."

Ongoing translational research in Dr. White's laboratory is focused on the development of novel models of therapy resistant models and understanding the influence of genetics on the pathophysiology, seizure-susceptibility and anti-epileptic drug pharmacology of animal seizure and epilepsy models. Dr. White and his colleagues at Utah and the NINDS are conducting research that may lead to novel therapies for treatment-resistant epilepsy and importantly, disease-modifying therapies with the potential to halt, slow, or prevent the development of epilepsy in susceptible individuals. He is also a scientific co-founder of NeuroAdjuvants, Inc., a Salt Lake City-based biotechnology firm focused on the development of metabolically stable, blood-brain-barrier neuropeptides for the treatment of refractory epilepsy and pain.

Dr. White earned his Ph.D. in Pharmacology in 1984 at the University of Utah and an M.S. in Pharmacology and baccalaureate degree in Pharmacy at Idaho State University. He began his career as a practicing pharmacist and since 1984 has risen through the academic ranks at the University of Utah. On November 18, 2011, Dr. White received an Honorary Doctor of Science from The University of Copenhagen Faculty of Pharmaceutical Sciences, Copenhagen, Denmark. Over the years, Dr. White has been the recipient of significant research funding from the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), and he and his collaborators have published over 170 original papers pertaining to the mechanism of action and the pharmacology of antiepileptic drugs. In addition to his academic service, Dr. White has served as Research Director of CURE (Citizen's United for Research in Epilepsy), the largest non-governmental provider of epilepsy research funding, since November 2011.

Epilepsy Foundation's Lifetime Accelerator Award
The Lifetime Accelerator Award was established in 2012 to honor physicians, scientists, industry leaders, and other individuals who have demonstrated a lifelong commitment to bringing new therapies to people living with epilepsy. Lifetime Accelerator Award recipients are chosen by an independent committee of global thought leaders and clinical investigators in epilepsy and seizure therapy discovery and development. Harvey Kupferberg, Ph.D., past chief of the Preclinical Pharmacology Section, Epilepsy Branch, NINDS, NIH, was conferred the 2012 Lifetime Accelerator Award, and Henrik Klitgaard, Ph.D., vice president, head CNS research, UCB, received the award in 2013. 

About Epilepsy
When a person has two or more unprovoked seizures, they have epilepsy, which affects more than 2 million people in the United States and 65 million people worldwide. This year, another 150,000 people in our country will be diagnosed with epilepsy. Despite all available treatments, four out of 10 people with epilepsy continue to experience uncontrolled seizures while many more experience less than optimal seizure control.

About the Epilepsy Foundation
The Epilepsy Foundation, a national non-profit with 48 affiliated organizations throughout the United States, has led the fight against seizures since 1968. The Foundation is an unwavering ally for individuals and families impacted by epilepsy and seizures. The mission of the Epilepsy Foundation is to stop seizures and sudden unexpected death in epilepsy (SUDEP), find a cure and overcome the challenges created by epilepsy through efforts including education, advocacy and research to accelerate ideas into therapies. The Foundation works to ensure that people with seizures have the opportunity to live their lives to their fullest potential. For additional information, please visit www.epilepsy.com.

"Like" the Epilepsy Foundation on Facebook at www.facebook.com/epilepsyfoundationofamerica and follow us on Twitter at www.twitter.com/epilepsyfdn

The following files are available for download:

Kim Macher
Vice President of the Epilepsy Therapy Project
Epilepsy Foundation
540.687.8077
[email protected] 

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
SYS-CON Events announced today that Nihon Micron will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Nihon Micron Co., Ltd. strives for technological innovation to establish high-density, high-precision processing technology for providing printed circuit board and metal mount RFID tags used for communication devices. For more inf...
SYS-CON Events announced today that Massive Networks, that helps your business operate seamlessly with fast, reliable, and secure internet and network solutions, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. As a premier telecommunications provider, Massive Networks is headquartered out of Louisville, Colorado. With years of experience under their belt, their team of...
SYS-CON Events announced today that Suzuki Inc. will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Suzuki Inc. is a semiconductor-related business, including sales of consuming parts, parts repair, and maintenance for semiconductor manufacturing machines, etc. It is also a health care business providing experimental research for...
"Our strategy is to focus on the hyperscale providers - AWS, Azure, and Google. Over the last year we saw that a lot of developers need to learn how to do their job in the cloud and we see this DevOps movement that we are catering to with our content," stated Alessandro Fasan, Head of Global Sales at Cloud Academy, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
21st International Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Me...
Enterprises are moving to the cloud faster than most of us in security expected. CIOs are going from 0 to 100 in cloud adoption and leaving security teams in the dust. Once cloud is part of an enterprise stack, it’s unclear who has responsibility for the protection of applications, services, and data. When cloud breaches occur, whether active compromise or a publicly accessible database, the blame must fall on both service providers and users. In his session at 21st Cloud Expo, Ben Johnson, C...
Many organizations adopt DevOps to reduce cycle times and deliver software faster; some take on DevOps to drive higher quality and better end-user experience; others look to DevOps for a clearer line-of-sight to customers to drive better business impacts. In truth, these three foundations go together. In this power panel at @DevOpsSummit 21st Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, industry experts will discuss how leading organizations build application success from all...
SYS-CON Events announced today that mruby Forum will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. mruby is the lightweight implementation of the Ruby language. We introduce mruby and the mruby IoT framework that enhances development productivity. For more information, visit http://forum.mruby.org/.
Cloud-based disaster recovery is critical to any production environment and is a high priority for many enterprise organizations today. Nearly 40% of organizations have had to execute their BCDR plan due to a service disruption in the past two years. Zerto on IBM Cloud offer VMware and Microsoft customers simple, automated recovery of on-premise VMware and Microsoft workloads to IBM Cloud data centers.
Why Federal cloud? What is in Federal Clouds and integrations? This session will identify the process and the FedRAMP initiative. But is it sufficient? What is the remedy for keeping abreast of cutting-edge technology? In his session at 21st Cloud Expo, Rasananda Behera will examine the proposed solutions: Private or public or hybrid cloud Responsible governing bodies How can we accomplish?
Today traditional IT approaches leverage well-architected compute/networking domains to control what applications can access what data, and how. DevOps includes rapid application development/deployment leveraging concepts like containerization, third-party sourced applications and databases. Such applications need access to production data for its test and iteration cycles. Data Security? That sounds like a roadblock to DevOps vs. protecting the crown jewels to those in IT.
SYS-CON Events announced today that Cedexis will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Cedexis is the leader in data-driven enterprise global traffic management. Whether optimizing traffic through datacenters, clouds, CDNs, or any combination, Cedexis solutions drive quality and cost-effectiveness.
Elon Musk is among the notable industry figures who worries about the power of AI to destroy rather than help society. Mark Zuckerberg, on the other hand, embraces all that is going on. AI is most powerful when deployed across the vast networks being built for Internets of Things in the manufacturing, transportation and logistics, retail, healthcare, government and other sectors. Is AI transforming IoT for the good or the bad? Do we need to worry about its potential destructive power? Or will we...
In his session at @ThingsExpo, Greg Gorman is the Director, IoT Developer Ecosystem, Watson IoT, will provide a short tutorial on Node-RED, a Node.js-based programming tool for wiring together hardware devices, APIs and online services in new and interesting ways. It provides a browser-based editor that makes it easy to wire together flows using a wide range of nodes in the palette that can be deployed to its runtime in a single-click. There is a large library of contributed nodes that help so...
IBM helps FinTechs and financial services companies build and monetize cognitive-enabled financial services apps quickly and at scale. Hosted on IBM Bluemix, IBM’s platform builds in customer insights, regulatory compliance analytics and security to help reduce development time and testing. In his session at 21st Cloud Expo, Lennart Frantzell, a Developer Advocate with IBM, will discuss how these tools simplify the time-consuming tasks of selection, mapping and data integration, allowing devel...